Catalyst Wire Dossier Catalyst Wire Dossier

IMBRUVICA

IBRUTINIB · Pharmacyclics LLC
Drug timelines are a Plus or Pro feature.

145 regulatory and trial events tracked for IMBRUVICA, covering 2013-06-19 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]

See pricing